Phaseline

Targets › POLB

POLB (DNA polymerase beta): drug programs, companies and trials

5 programs from 3 companies in 11 trials: 6 Phase 3, 3 Phase 2, 1 Phase 1, 1 Phase 4; Infectious disease, Oncology, Neurology; next expected readout Nov 2026.

Repair polymerase that plays a key role in base-excision repair. During this process, the damaged base is excised by specific DNA glycosylases, the DNA backbone is nicked at the abasic site by an apurinic/apyrimidic (AP) endonuclease, and POLB removes 5'-deoxyribose-phosphate from the preincised AP site acting as a 5'-deoxyribose-phosphate lyase (5'-dRP lyase); through its DNA polymerase activity, it adds one…. (UniProt, P06746)

Open in Phaseline: the race on POLB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
José Antonio Mata MarínDarunavir
Human immunodeficiency virus type 1 protease inhibitor
CYP3A4, POLBPhase 4HIV InfectionNov 2026
Sun Yat-sen UniversityEntecavir
DNA polymerase/reverse transcriptase inhibitor
POLG, POLBPhase 3Gastrointestinal Cancers; Resolved Hepatitis BDec 2026
Gilead SciencesTenofovir Disoproxil Fumarate
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
POLA1, POLBPhase 3Chronic Hepatitis B; Hepatitis B; Hepatitis B Infection; Parkinson DiseaseJul 2027
Gilead SciencesIslatravir
Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor
RT, IN, POLB, INTS1, INTS8Phase 3HIV-1-Infection; HIV-1-infection; HIV-1 InfectionMar 2028
Gilead SciencesISL/LEN FDC
Fixed-dose combination of nucleotide reverse transcriptase translocation inhibitor and HIV
POLB, GAGPhase 2HIV-1 InfectionMar 2028

Conditions

HIV-1 Infection (2) Gastrointestinal Cancers (1) Resolved Hepatitis B (1) HIV-1-Infection (1) HIV-1-infection (1) Chronic Hepatitis B (1) Hepatitis B (1) Hepatitis B Infection (1) Parkinson Disease (1) HIV Infection (1)

Modalities

small molecule (5)

Companies

Gilead Sciences (3) Sun Yat-sen University (1) José Antonio Mata Marín (1)

Related targets

POLG (1) RT (1) IN (1) INTS1 (1) INTS8 (1) POLA1 (1) GAG (1) CYP3A4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.